BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase III data

Top-line data from the Phase III AVANT trial in 3,451 patients who had undergone surgery for high-risk stage II and III colon cancer showed that Avastin plus FOLFOX or XELOX chemotherapy missed the primary endpoint of significantly improving disease-free survival vs. FOLFOX chemotherapy alone. Additionally, more patients receiving Avastin plus chemotherapy relapsed at 3 years of follow up vs. chemotherapy alone. Roche said it is evaluating data from...

Read the full 330 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >